Taking advantage of the pros of decentralized trials while mitigating any negative impacts from the cons will be central to future success, along with logical mapping of the decision processes involved in study design.
A Black History Month Q&A with ACRP Diversity Advisory Council member Dr. Otis Johnson on efforts to improve diversity within the clinical trials ecosystem.
Elements of decentralized clinical trials are changing the conduct of human subjects research everywhere you look, and academic medical centers are poised to take advantage of the latest trends and technologies.
Nationwide Children's Hospital in Columbus, Ohio, has invested more than $4 million in an intramural funding program over the last 10 years, that is designed to promote, support, and encourage fellows and early-level faculty in conducting clinical and translational research.
Since the pandemic, the U.S. Food and Drug Administration’s Expanded Access pathway has been featured in headlines as a mechanism by which unapproved but potentially beneficial treatments were given to patients outside randomized clinical trials.